Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung

NCT02443337 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02443337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02443337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2015
Completion date
September 30, 2017
Enrollment
31 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer metastatic